COVID-19

It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South Africa and the UK. Please find Part 1 of this interview available here. To access […]

It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here. To access more […]

It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19. Useful Resources: Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A […]

It was a great pleasure to meet with Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Athens, Greece) to discuss phase 3 SAVE-MORE study assessing the effect of anakinra for the treatment of patients with COVID-19 pneumonia. Useful Resources: Publication available to access here: https://www.nature.com/articles/s41591-021-01499-z Questions: Could you give us a brief overview of the role of […]

It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines. His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL […]

touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19. The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the […]

It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B. Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at […]

We were delighted to have the opportunity to speak with Dr Alba Grifoni ( La Jolla Institute for Immunology, La Jolla, CA, USA) to discuss T Cell responses of SARS-CoV-2 epitopes in COVID-19 cases. Her abstract entitled: ‘B & T cell interactions: New studies on COVID-19’ (SY08.05) was presented at the HIVR4P Virtual Conference 2021, […]

It was a delight to be able to speak with Dr Carlos Chaccour (University of Barcelona, Barcelona, Spain) about the controversy currently surrounding the use of ivermectin for the treatment of COVID-19. His presentation entitled Ivermectin and COVID: what’s going on?  was presented at the ISNTD d3 2021 Virtual Congress, 24-25 February. Questions: Could you […]